Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with >95% vaccine coverage, Israel 2013

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 1057-1064

  Shulman, Lester M ^a   Martin, Javier ^b   Sofer, Danit ^a   Burns, Cara C ^c   Manor, Yossi ^a   Hindiyeh, Musa ^a   Gavrilin, Eugene ^d   Wilton, Thomas ^b   Moran Gilad, Jacob ^a   Gamzo, Ronni ^a   Mendelson, Ella ^a   Grotto, Itamar ^a  

^a MINISTRY OF HEALTH   (Israel)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

environmental surveillance; neurovirulence; neutralizing antigenic epitopes; poliovirus receptor; wild type 1 poliovirus

Indexed keywords

EPITOPE; POLIOMYELITIS VACCINE; CAPSID PROTEIN; VIRUS ANTIGEN;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; CELL CULTURE; CHILD; DISEASE SURVEILLANCE; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN POLIOVIRUS 1; IN VITRO STUDY; ISRAEL; MOUSE; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; RECEPTOR BINDING; SEQUENCE ANALYSIS; SEWAGE TREATMENT PLANT; SOUTH ASIA; VACCINATION; VIRUS CAPSID; VIRUS TRANSMISSION; WILD TYPE; ANIMAL; CLASSIFICATION; DNA SEQUENCE; EPIDEMIOLOGY; FECES; FEMALE; GENETICS; GENOTYPE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MOLECULAR GENETICS; PATHOGENICITY; PHENOTYPE; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; SEQUENCE HOMOLOGY; SERODIAGNOSIS; TRANSGENIC MOUSE; VIROLOGY; VIRULENCE; WISTAR RAT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, VIRAL; CAPSID PROTEINS; CHILD; CHILD, PRESCHOOL; ENVIRONMENTAL MICROBIOLOGY; FECES; FEMALE; GENOTYPE; HUMANS; ISRAEL; MALE; MICE, TRANSGENIC; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PHENOTYPE; POLIOVIRUS; RATS, WISTAR; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRULENCE; YOUNG ADULT;

EID: 84926656468     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1136     Document Type: Article

References (37)

1. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. Philadelphia, PA: Saunders/Elsevier, 2008:605-29.
2. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 5th ed. Philadelphia, PA: Saunders/Elsevier, 2008:631-85.
3. Swartz TA. The epidemiology of polio in Israel: an historical perspective. Tel Aviv: Dyonon Pub, Ltd, 2008.
4. Shulman LM, Handsher R, Yang CF, et al. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J Clin Microbiol 2000; 38:945-52.
5. Manor Y, Handsher R, Halmut T, et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J Clin Microbiol 1999; 37:1670-5.
6. Slater PE, OrensteinWA, Morag A, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990; 335:1192-5; discussion 6-8.
7. Hovi T, Shulman LM, van der Avoort H, Deshpande J, Roivainen M, De Gourville EM. Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol Infect 2012; 140:1-13.
8. Shulman LM. Polio and its epidemiology. In: Meyers RA, ed. Encyclopedia of sustainability science and technology. New York: Springer, 2012:8123-73.
9. Shulman LM, Manor Y, Sofer D, Mendelson E. Bioterrorism and surveillance for infectious diseases-lessons from poliovirus and enteric virus surveillance. J Bioterr Biodef 2012; doi:10.4172/2157-2526.S4-004.
10. Kew OM, Mulders MN, Lipskaya GY, de Silva E, Pallansch MA. Molecular epidemiology of polioviruses. Semin Virol 1995; 6:401-5.
11. World Health Organization. WHO-recommended surveillance standard of poliomyelitis. Geneva, Switzerland: WHO, 2013.
12. Manor Y, Blomqvist S, Sofer D, et al. Advanced environmental surveillance and molecular analyses indicate separate importations rather than endemic circulation of wild type 1 poliovirus in Gaza district in 2002. Appl Environ Microbiol 2007; 73:5954-8.
13. Manor Y, Handsher R, Halmut T, et al. A double-selective tissue culture system for isolation of wild-Type poliovirus from sewage applied in a long-Term environmental surveillance. Appl Environ Microbiol 1999; 65:1794-7.
14. Anis E, Kopel E, Singer SR, et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro Surveill 2013; 18.
15. Manor Y, Shulman LM, Hindiyeh M, et al. Intensified environmental surveillance supporting the response to wild-Type poliovirus type 1 silent circulation in Israel, 2013. Euro Surveill 2014; 19:pii:20708.
16. Shulman LM, Gavrilin E, Jorba J, et al. Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. Euro Surveill 2014; 19:pii:20709.
17. Kopel E, Kaliner E, Grotto I. Lessons from a public health emergency-importation of wild poliovirus to Israel. N Engl J Med 2014; 371: 981-3.
18. Kilpatrick DR, Iber JC, Chen Q, et al. Poliovirus serotype-specific VP1 sequencing primers. J Virol Methods 2011; 174:128-30.
19. Hindiyeh MY, Moran-Gilad J, Manor Y, et al. Development and validation of a quantitative RT-PCR assay for investigation of wild type poliovirus 1 (SOAS) reintroduced into Israel. Euro Surveill 2014; 19: pii:20710.
20. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J Virol 2003; 77:8366-77.
21. Odoom JK, Yunus Z, Dunn G, Minor PD, Martin J. Changes in population dynamics during long-Term evolution of Sabin type 1 poliovirus in an immunodeficient patient. J Virol 2008; 82:9179-90.
22. Albrecht P, van Steenis G, van Wezel AL, Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984; 6(suppl 2): S540-4.
23. Karber G. 50% end-point calculation. Arch Exp Pathol Pharmak 1931; 162:480-3.
24. Council of Europe. In vivo assay of poliomyelitis vaccine (inactivated). Eur Monogr 2008; 01/2008:20720:225-6.
25. Bassal R, Shohat T, Cohen D, et al. Survey to determine the level of vaccine coverage against poliovirus in the general population of Israel [in Hebrew]. Document 353, Israel Center for Disease Control, 2013.
26. Sutter RW, Patriarca PA, Brogan S, et al. Outbreak of paralytic poliomyelitis in Oman: evidence for widespread transmission among fully vaccinated children. Lancet 1991; 338:715-20.
27. World Health Organization. Polio in the Syrian Arab Republic-update. Geneva, Switzerland: WHO, 2013.
28. Hovi T, Cantell K, Huovilainen A, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986; 1:1427-32.
29. Drexler JF, Grard G, Lukashev AN, et al. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc Natl Acad Sci U S A 2014; 111:12889-94.
30. Le Menach A, Llosa AE, Mouniaman-Nara I, et al. Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010-February 2011. Emerg Infect Dis 2011; 17:1506-9.
31. Centers for Disease Control and Prevention. Poliomyelitis outbreak-Republic of the Congo, September 2010-February 2011. MMWR Morb Mortal Wkly Rep 2011; 60:312-3.
32. Swartz TA, Handsher R, Manor Y, et al. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis. Vaccine 1998; 16:2090-5.
33. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163:1-6.
34. Laassri M, Lottenbach K, Belshe R, et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005; 192:2092-8.
35. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005; 191:990-9.
36. Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012; 8:e1002599.
37. Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999; 162:5011-8.